Apoptotic Effect of Tamoxifen on Hepatocellular Carcinoma HepG 2 Cell Line
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer, and the third most common cause of cancer-related death worldwide (I asked do my excel homework for me to get verified statistics that I used in this research, so I have examples to use to prove or disprove the thesis in the paper). Major causes of hepatocellular carcinoma include hepatitis B, hepatitis C, alcoholic liver disease, and possibly nonalcoholic steatohepatitis. Tamoxifen (TAM) inhibits proliferation and induces apoptosis in many cancers such as breast cancer cell, gastric cancer BGC823 cell, SK-HEP-1 hepatoblasma cells and human cholangiocarcinoma cells. The aim of the present study was to analyze the apoptotic and antiprolifrative effect of TAM in the hepatocellular carcinoma HepG2 cell line. Materials and Methods: Cells were treated with various concentration of TAM and the MTT assay was used and then cells were treated with single dose of TAM (25μM) and flow cytometry assay was performed. Results: TAM inhibited the growth of HepG2 cells and induced apoptosis significantly with a time- and dose-dependent manner. Discussion: Our finding clearly indicated that TAM has a significant inhibitory effect and induces apoptosis with a dose- and time-dependent manner. Conclusion: TAM can significantly inhibit the growth of HepG2 cells and plays a significant role in apoptosis of this cell line.
Full Text:
PDFReferences
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
Brulx J, Sherman M; Practice Guidlines Committee, American Association For the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
EL-serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230.
Prince AM, Szmuness W, Michon J, et al. A case/control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer. 1975;16 (3):376–383.
Nishioka K, Levin AG, Simons MJ. Hepatitis B antigen, antigen subtypes, and hepatitis B antibody in normal subjects and patients with liver disease. Bull World Health Organ. 1975; 52(3):293–300.
Trichopoulos D, Tabor E, Gerety RJ, et al. Hepatitis B and primary hepatocellular carcinoma in a European population. Lancet. 1978; 2(8102):1217–1219.
Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989; 2(8670):1004–1006.
Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet. 1990; 335(8694):873–874.
Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA. 1991; 265(15):1974–1976.
International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis Viruses. Volume 59. Lyon, France: IARC; 1994.
Trichopoulos D, MacMahon B, Sparros L, Merikas G. Smoking and hepatitis B-negative primary hepatocellular carcinoma. J Natl Cancer Inst. 1980; 65(1):111–114.
Fisher B, Constantino JP, Wickerham CD, Redmond Ck, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371–1388
McKeon VA. The breast cancer prevention trial: should women at high risk take tamoxifen? J Obstet Gynecol Neonatal Nurs. 1999; 28:34–38
Radmacher MD, Simon R 2000 Estimation of tamoxifens’s efficiency for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92:48–53 15.
Early Breast Cancers Trialist′s Collaborative Group 1998 Tamoxifen for an early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467 20.
Otto A, Paddenberg R, Schubert S, Mannhertz H 1996 Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 22:603–612
Perry R, Kang Y, Greaves B 1995 Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238–245
Lehenkari P, Parikka V, Rautiala TJ, Weckstrom M, Dahllund J, Härkönen PL, Väänänen HK 2003 The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res 18:473–478
Couldwell WT, Hinton DR, He S 1994 Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345:43–46 20.
Gelmann EP 1997 Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24:S65–S70
Heerdt AS, Borgen PI 1999 Current status of tamoxifen use: an update for the surgical oncologist. J Surg Oncol 72:42–49
Custodio JB, Moreno AJ, Wallace KB 1998 Tamoxifen inhibits induction of the mitochondrial permeability transition by Ca2+ and inorganic phosphate. Toxicol Appl Pharmacol 152:10–17
Yan Li , Hao Deng, Jun Fan et al. Tamoxifen-mediated apoptosis relationship with ERα36 in gastric cancer cell BGC823. Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL
Kim JA, Kang YS, Jung MW, Lee SH, Lee YS. Involvment of Ca2+ influx in the mechanism of tamoxifen-induced apoptosis in HepG2 human hepatoblastoma cell. Cancer lett 1999; 147: 115-123
Hashimoto Y, Hibasami H, Tamaki S, Kamei A, Ikoma J, Kaito M, Imoto I, Watanabe S, Nakashima K, Adachi Y. Induction Of Apoptotic Cell Death In Human Hepatocellular Carcinoma SK-HEP-1 Cells By A Polyamine Synthesis Inhibitor, Methylglyoxal Bis (Cyclopentylamidinohydrazone). Anticancer Drugs 1999; 10: 323-327
Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609–1618
George Pan, Selwyn M. Vickers, Allan Pickens, et al. Apoptosis and Tumorigenesis in Human Cholangiocarcinoma Cells. American Journal of Pathology, 1999. Vol. 155, No. 1
Yu MC, Yuan JM, Lu SC. Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23(suppl 1):S92–S97.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.
Poon D, Anderson BO, Chen LT et al. Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111–1118.
Montalto G, Cervello M, Giannitrapani L et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963:13–20.
Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300–4308.
Sebastian Brandt, Hartmut Heller, Klaus-Dieter Schuster et al. Tamoxifen induces suppression of cell viability and apoptosis in the human hepatoblastoma cell line HepG2 via down-regulation of telomerase activity. Liver International. 2004, 24 (1); 46–54
Renhua Guo, Zuhu Huang, Yongqian Shu. Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomedicine & Pharmacotherapy. 2009; 63(5): 375–379
Lorenzo K. Sampson, Selwyn M. Vickers, Weizhong Ying et al. Tamoxifen-mediated Growth Inhibition of Human Cholangiocarcinoma. Cancer research. 1997; 5: 1931-1940
F.E. van Leeuwen, MSPH,, A.W. van den Belt-Dusebout, F.E. van Leeuwen et al. Risk of endometrial cancer after tamoxifen treatment of breast. The lancet. 1994; 433: 448–452
Philip Carthew, Richard E. Edwards, Barbara M. Nolan et al. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis (2000) 21 (4): 793-797.
Jin-Yun Hwang, Bi-Yu Lin, Fen-Mei Tang et al. Tamoxifen Stimulates Human Papillomavirus Type 16 Gene Expression and Cell Proliferation in a Cervical Cancer Cell Line. Cancer research. 1992; 4: 1916-1930
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright ©2022 Academic Journals Center
To make sure that you can receive messages from us, please add the 'academicjournalscenter.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.